NZ Neurology Research Review Issue 51 - MS Focus

In this issue:

Risk markers for faster progression of MS
MS trends in Denmark
PML after fingolimod treatment
PML and JCV in natalizumab recipients
Switching from fingolimod to alemtuzumab in RRMS
Efficacy and safety of rituximab in RRMS
Positive effects of fampridine on cognition, fatigue and depression in MS
Persistence with treatment in the new MS era
Natalizumab vs fingolimod for second-line treatment in RRMS
Switching from natalizumab to dimethyl fumarate in RRMS

Please login below to download this issue (PDF)

Subscribe